Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Abstract | AIM: RESULTS: During the period January 2005-December 2009, 53 with acute myeloid leukemia received two cycles of the 3+7 protocol as a first-line standard-dose remission-induction therapy ( ARA-C, days 1-7 and daunorubicin, days 1-3). The HiDAC (5 patients), MiDAC (7 patients), and FLAG-IDA protocols (3 patients) were given as salvage therapy. None of these patients achieved CR. There were 27 (51%) males and 26 (49%) females (median age, 55 years, range 28-76). The median white blood cell count was 53 (range 0.9 -350)×10(9)/L, platelets 44 (range 3-856×10(9)/l) and bone marrow blasts 67%. HCT-IC comorbidity scores were 3 in two (3.8%) patients, 2 in 11 (20.8%), 1 in 12 (22.6%) and 0 in 16 (30.2%) patients. Median OS was 3.9 months (range 1 -20 months). The hepatomegaly, white blood cell count, ECOG PS, serum level of lactate dehydrogenase, dysplastic changes, coexpression of CD64, CD15, CD11b, comorbidities and disease cytogenetics influenced survival. CONCLUSION: This single-center study evaluated the significance of pretreatment factors, and found that patient age, comorbidities, ECOG performance status, leukocytosis, hepatomegaly, LDH, and the disease cytogenetics were factors which influenced the outcomes of primary resistant patients with acute myeloid leukemia. An understanding of these factors may help to predict OS in cases where CR has not been achieved and may help when making further treatment decisions.
|
Authors | N Colovic, D Tomin, A Vidovic, N Suvajdzic, G Jankovic, V Palibrk, I Djunic, V Djurasinovic, M Virijevic |
Journal | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
(Biomed Pharmacother)
Vol. 66
Issue 8
Pg. 578-82
(Dec 2012)
ISSN: 1950-6007 [Electronic] France |
PMID | 23085253
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Masson SAS. All rights reserved. |
Chemical References |
- Biomarkers, Tumor
- Hemoglobins
- Cytarabine
- Etoposide
- Daunorubicin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Biomarkers, Tumor
(analysis, biosynthesis)
- Blood Cell Count
- Bone Marrow Cells
(metabolism, pathology)
- Comorbidity
- Cytarabine
(administration & dosage, therapeutic use)
- Daunorubicin
(administration & dosage, therapeutic use)
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Etoposide
(administration & dosage, therapeutic use)
- Female
- Hemoglobins
(analysis)
- Humans
- Immunophenotyping
- Kaplan-Meier Estimate
- Karyotyping
- Kidney Function Tests
- Leukemia, Myeloid, Acute
(blood, drug therapy, genetics, mortality)
- Liver Function Tests
- Logistic Models
- Male
- Middle Aged
- Prognosis
- Remission Induction
- Risk Factors
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|